News und Analysen
Rule Breaker Mailbag: Is Corporate Leadership Really as Important as the Fool Says?
In this segment from Rule Breaker Investing, Motley Fool co-founder David Gardner attempts to answer a Foolish investor who is skeptical that the leadership ability and style of CEOs and executive
Rule Breaker Mailbag: Is Corporate Leadership Really as Important as the Fool Says?
In this segment from Rule Breaker Investing, Motley Fool co-founder David Gardner attempts to answer a Foolish investor who is skeptical that the leadership ability and style of CEOs and executive
Why Kinder Morgan, Ambac Financial, and Sarepta Therapeutics Jumped Today
Stocks didn't move much on Thursday, and major benchmarks were narrowly mixed as earnings season kicked into full gear. Healthcare and utility stocks were generally higher, but the industrials and
BOIRON : Activité du premier semestre 2017
ACTIVITÉ BOIRON PREMIER SEMESTRE 2017
(Données non auditées)
ACTIVITÉ CUMULÉE À FIN JUIN 2017
en milliers d'euros
2016
2017
Var. taux courant 2017/2016
Var. taux constant....
BOIRON : 2017 half-year activity
BOIRON 2017 HALF-YEAR ACTIVITY
(Unaudited data)
CUMULATIVE ACTIVITY AS OF THE END OF JUNE 2017
in thousands of euros
2016
2017
Variation at current exchange rates
Variation....
Why Sarepta Therapeutics Stock Rose After-Hours Wednesday
Shares of the orphan drug specialist Sarepta Therapeutics (NASDAQ: SRPT) rose by as much as 15.5% in after-hours trading yesterday on heavy volume. This double-digit rally was sparked by a far
Why Sarepta Therapeutics Stock Is Rising Today
Shares of the orphan drug specialist Sarepta Therapeutics (NASDAQ: SRPT) rose by as much as 15.5% in after-hours trading yesterday on heavy volume. This double-digit rally was sparked by a far
Vertex Pharmaceuticals Stock Is Soaring: Here's Why It's Still Not Too Late to Buy
Just last week, I wrote why you'd be smart to buy Vertex Pharmaceuticals (NASDAQ: VRTX) stock. At that time, Vertex was up around 70% for the year. My argument then was that the stock was still
Vertex Pharmaceuticals Stock Is Soaring: Here's Why It's Still Not Too Late to Buy
Just last week, I wrote why you'd be smart to buy Vertex Pharmaceuticals (NASDAQ: VRTX) stock. At that time, Vertex was up around 70% for the year. My argument then was that the stock was still
Vertex Pharmaceuticals Stock Is Soaring: Here's Why It's Still Not Too Late to Buy
Just last week, I wrote why you'd be smart to buy Vertex Pharmaceuticals (NASDAQ: VRTX) stock. At that time, Vertex was up around 70% for the year. My argument then was that the stock was still
Here's Why Inovio Pharmaceuticals, Inc. Stock Fell Today
Shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO), a clinical-stage biotech with a focus on cancer and infectious diseases, fell 13.4% during Wednesday's session. An announcement on Tuesday that
Intuitive Surgical, Inc. in 3 Charts
It's still early, but Intuitive Surgical (NASDAQ: ISRG) stock could be on track to turn in its best performance of this decade. Shares of the robotic surgical systems company are up nearly 50% so far
5 Off-the-Radar Numbers to Take Note of in Johnson & Johnson's Second-Quarter Report
It's officially earnings season, which can only mean one thing: Johnson & Johnson (NYSE: JNJ) is kicking things off for big pharmaceutical companies.On Tuesday morning, July 18, Johnson & Johnson
5 Off-the-Radar Numbers to Take Note of in Johnson & Johnson's Second-Quarter Report
It's officially earnings season, which can only mean one thing: Johnson & Johnson (NYSE: JNJ) is kicking things off for big pharmaceutical companies.On Tuesday morning, July 18, Johnson & Johnson
Here's Why AVEO Oncology Rose as Much as 15% Today
Shares of biopharma AVEO Oncology (NASDAQ: AVEO) rose up to 15% this morning as the nearly monthlong momentum continued to keep the roller-coaster ride going. While there has been a steady
Why Vertex Pharmaceuticals Incorporated Stock Is Soaring Today
Shares of rare-disease drugmaker Vertex Pharmaceuticals (NASDAQ: VRTX) are on the rise this morning thanks to the extremely positive data readouts for three trials assessing three different triple
Why Vertex Pharmaceuticals Incorporated Stock Is Soaring Today
Shares of rare-disease drugmaker Vertex Pharmaceuticals (NASDAQ: VRTX) are on the rise this morning thanks to the extremely positive data readouts for three trials assessing three different triple
Why Vertex Pharmaceuticals Incorporated Stock Is Soaring Today
Shares of rare-disease drugmaker Vertex Pharmaceuticals (NASDAQ: VRTX) are on the rise this morning thanks to the extremely positive data readouts for three trials assessing three different triple
These 4 Marijuana Stocks All Jumped at Least 10% Last Week
The legal marijuana industry has been a monster in terms of growth, and marijuana stock investors have taken notice. In fact, a majority of pot stocks have doubled or tripled in value over the
3 Stocks to Supplement Your Social Security Income
Most American retirees depend on Social Security for at least half their retirement income. While it has been a reliable source of income for generations, Social Security's future looks a lot shakier
3 Stocks to Supplement Your Social Security Income
Most American retirees depend on Social Security for at least half their retirement income. While it has been a reliable source of income for generations, Social Security's future looks a lot shakier
Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics
Celldex Therapeutics (NASDAQ: CLDX) and Juno Therapeutics (NASDAQ: JUNO) are both once-promising clinical-stage biotechs that have fallen on extremely hard times of late. Over the past two and half
Does Puma Biotechnology's Approval Make It Worth More?
Puma Biotechnology's (NASDAQ: PBYI) roller-coaster ride to approval is finally over. After fits and starts in clinical trials, the FDA gave the company's breast cancer drug, Nerlynx, a green light
Does Puma Biotechnology's Approval Make It Worth More?
Puma Biotechnology's (NASDAQ: PBYI) roller-coaster ride to approval is finally over. After fits and starts in clinical trials, the FDA gave the company's breast cancer drug, Nerlynx, a green light
UnitedHealth Group's Sales Surge Above $50 Billion, Despite Exiting Obamacare
UnitedHealth Group's (NYSE: UNH) decision to stop selling Obamacare plans this year hasn't dented its momentum. The nation's biggest health insurer reported sales of $50 billion in the second quarter